<DOC>
	<DOC>NCT00555321</DOC>
	<brief_summary>The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant</brief_summary>
	<brief_title>Belatacept in Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>First time recipient of deceased donor liver transplant Age 1870 Hepatitis C virus (HCV) positive recipients For Longterm extension studySubjects who have completed one year of study treatment (through Week 52) Target Disease Exclusions: Donor Exclusions a) Living donors b) ABOincompatible donor recipient pairs c) Donor age &lt; 12 or &gt; 65 years d) Non heartbeating donors e) Anticipated cold ischemia time &gt; 14 hours f) Donor Disease i) Known Human immunodeficiency virus (HIV) infection ii) Hepatitis B virus (HBV) surface antigenpositive or polymerase chain reaction (PCR)positive donor if HBV negative recipient iii) HCV antibodypositive or PCR positive donor if HCV negative recipient Recipient Exclusions g) Subjects with a history of hypercoagulable state h) Subjects with fulminant hepatic failure i) Subjects receiving a split or reduced liver j) Subjects who are EpsteinBarr virus (EBV) negative Medical History and Concurrent Diseases 1. Subjects who have received 2 or more consecutive weeks of dialysis 1 month prior to enrollment OR anticipated to have prolonged dialysis posttransplantation 2. Subjects with known intrinsic renal disease (e.g., a urine protein/ creatinine ratio &gt; 150 mg/g or the presence of an abnormal number of red blood cells (RBCs) or granular casts in the urine) AND calculated GFR &lt; 40 ml/min/1.73 m^2 body surface area (BSA) (abbreviated Modification of Diet in Renal Disease [MDRD]). Subjects must have a calculated GFR assessment within 1 month prior to enrollment. 3. Subjects with known HIV 4. Subjects with any prior or concurrent solid organ (e.g., heart, kidney, pancreas) or cell (e.g., islet, bone marrow) transplant or subjects deemed likely to have a second solid organ or cell transplant (e.g., islet, bone marrow) within the next 3 years. 5. Subjects with a history of cancer within the last 5 years Allergies and Adverse Drug Reactions a) Hypersensitivity to any medications that will be used in the protocol Prohibited Treatments and/or Therapies 1. Subjects receiving immunosuppressive agent(s) (e.g., methotrexate, abatacept, infliximab, etanercept, chemotherapy, etc.) within the past 6 months for other indications such as an autoimmune disease 2. Subjects who received maintenance corticosteroids at a dose of &gt; 5 mg/day of prednisone (or equivalent) for at least 7 consecutive days within the prior year for an underlying chronic inflammatory or autoimmune disease 3. Subjects who have used any investigational drug within 30 days prior to the Day 1 visit 4. Subjects previously treated with belatacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>